Condition
Stage IVB Hepatocellular Carcinoma
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (3)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03211416Phase 1Completed
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
NCT02072486Not ApplicableCompleted
Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT02837029Phase 1Completed
Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer
NCT02507765Phase 1Completed
Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Showing all 4 trials